Home

OrbiMed Advisors Israel II Ltd

CIK 1682093 · last filed 2024-10-17

OrbiMed Advisors Israel II Ltd is a corporate insider who has filed 13 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for ACET, was dated Apr 8, 2026. Across all open-market trades the lifetime net is +$208.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $26.7M across reported positions. The firm reports its address in New York, NY. 29 SEC filings were submitted jointly with OrbiMed Israel GP II, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$26.69M

Companies

3

Total Filings

13

Lifetime Open-Market Net

$208.14M

Filer Profile

Reported Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Phone
(212) 739-6400
State of Incorporation
Cayman Islands
Related Filers
OrbiMed Israel GP II, L.P. — 29 joint filings, latest 2026-04-09
ORBIMED ADVISORS LLC — 28 joint filings, latest 2026-04-09
OrbiMed Capital GP VI LLC — 17 joint filings, latest 2026-04-09
OrbiMed Genesis GP LLC — 15 joint filings, latest 2026-04-09
OrbiMed Capital GP VII LLC — 9 joint filings, latest 2023-08-17
OrbiMed Capital GP V LLC — 8 joint filings, latest 2026-04-09
OrbiMed Israel BioFund GP Limited Partnership — 8 joint filings, latest 2026-04-09
OrbiMed Israel GP Ltd. — 8 joint filings, latest 2026-04-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
UPB Director 4,554,873 $5.73 $26.10M $56.10M 1 2024-10-17
ACET Director 61,891 $9.52 $589.2K $60.00M 2 2024-01-26
LogicBio Therapeutics, Inc. (LOGC) Delisted Director 3,524,997 $7.06 $24.89M $92.04M 2 2020-10-05

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-08 ACET Notice (144) −40,416 -$264.7K EDGAR
2024-10-17 UPB Mixed +17,739,156 $56.10M EDGAR
2024-01-26 ACET Buy (P) +25,000,000 $60.00M EDGAR
2023-10-02 DMRA Notice (144) −244,527 -$176.1K EDGAR
2023-08-30 DMRA Notice (144) −510,610 -$296.2K EDGAR
2023-08-21 DMRA Notice (144) −631,048 -$389.4K EDGAR
2023-08-15 DMRA Notice (144) −489,970 -$367.5K EDGAR
2023-07-31 DMRA Notice (144) −180,300 -$544.5K EDGAR
2023-07-25 DMRA Notice (144) −4,700 -$11.0K EDGAR
2023-07-13 DMRA Notice (144) −52,800 -$134.6K EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.